Android app on Google Play

Cypress Bioscience (CYPB) Says Phase IIa Trials Don't Support Continuing Development Program to Evaluate Combinations of Mirtazapine

June 27, 2006 3:09 PM EDT Send to a Friend
Get Alerts CYPB Hot Sheet
Trade CYPB Now!
Join SI Premium – FREE
Cypress Bioscience Inc. (NASDAQ: CYPB) announced that results of recently completed Phase IIa trials do not support continuing a development program evaluating combinations of mirtazapine with another approved drug as potential pharmaceutical treatments for obstructive sleep apnea (OSA).

Cypress and Organon, the human healthcare business unit of Akzo Nobel, had each independently conducted Phase IIa trials that served as the basis for today's announcement. A previous independently conducted small preliminary investigator sponsored pilot trial found that mirtazapine was able to reduce the number of abnormal respiratory events over the course of the night by roughly fifty percent. However, those data were not replicated in the recently completed phase IIa trials.

The companies are mutually exploring new potential opportunities to continue the collaboration.



You May Also Be Interested In


Related Categories

FDA

Add Your Comment